Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice.

Mitchell SJ, Bernier M, Aon MA, Cortassa S, Kim EY, Fang EF, Palacios HH, Ali A, Navas-Enamorado I, Di Francesco A, Kaiser TA, Waltz TB, Zhang N, Ellis JL, Elliott PJ, Frederick DW, Bohr VA, Schmidt MS, Brenner C, Sinclair DA, Sauve AA, Baur JA, de Cabo R.

Cell Metab. 2018 Mar 6;27(3):667-676.e4. doi: 10.1016/j.cmet.2018.02.001.

2.

SRT1720 improves survival and healthspan of obese mice.

Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martín-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R.

Sci Rep. 2011;1:70. doi: 10.1038/srep00070. Epub 2011 Aug 18. Erratum in: Sci Rep. 2013;3():1131.

3.

Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.

Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ.

Cancer Prev Res (Phila). 2011 Sep;4(9):1419-25. doi: 10.1158/1940-6207.CAPR-11-0148. Epub 2011 Jun 16.

4.

Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells.

Breitenstein A, Stein S, Holy EW, Camici GG, Lohmann C, Akhmedov A, Spescha R, Elliott PJ, Westphal CH, Matter CM, Lüscher TF, Tanner FC.

Cardiovasc Res. 2011 Feb 1;89(2):464-72. doi: 10.1093/cvr/cvq339. Epub 2010 Oct 26.

5.

Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo.

Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, Galonek HL, Israelian K, Song J, Razvadauskaite G, Lynch AV, Carney DP, Johnson RJ, Lavu S, Iffland A, Elliott PJ, Lambert PD, Elliston KO, Jirousek MR, Milne JC, Boss O.

BMC Syst Biol. 2009 Mar 10;3:31. doi: 10.1186/1752-0509-3-31.

6.

AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.

Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J.

Nature. 2009 Apr 23;458(7241):1056-60. doi: 10.1038/nature07813.

7.

Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation.

Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J.

Cell Metab. 2008 Nov;8(5):347-58. doi: 10.1016/j.cmet.2008.08.017. Erratum in: Cell Metab. 2009 Feb;9(2):210.

8.

Sirtuins--novel therapeutic targets to treat age-associated diseases.

Lavu S, Boss O, Elliott PJ, Lambert PD.

Nat Rev Drug Discov. 2008 Oct;7(10):841-53. doi: 10.1038/nrd2665. Review. Erratum in: Nat Rev Drug Discov. 2009 Jun;8(6):516.

PMID:
18827827
9.

Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.

Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R.

Cell Metab. 2008 Aug;8(2):157-68. doi: 10.1016/j.cmet.2008.06.011. Epub 2008 Jul 3.

10.

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.

Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.

J Natl Cancer Inst. 2008 May 7;100(9):649-62. doi: 10.1093/jnci/djn113. Epub 2008 Apr 29.

11.

Sirtuins: novel targets for metabolic disease.

Elliott PJ, Jirousek M.

Curr Opin Investig Drugs. 2008 Apr;9(4):371-8. Review.

PMID:
18393104
12.

The influence of corticosteroids on the release of novel biomarkers in human endotoxemia.

de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T.

Intensive Care Med. 2008 Mar;34(3):518-22. Epub 2007 Dec 14.

13.

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH.

Nature. 2007 Nov 29;450(7170):712-6.

14.

Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia.

de Kruif MD, Lemaire LC, Giebelen IA, Groot AP, Pater JM, van den Pangaart PS, Elliott PJ, van der Poll T.

Shock. 2008 Apr;29(4):458-61.

PMID:
17909456
15.

Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.

de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, Groot AP, de Vos AF, Elliott PJ, Meijers JC, Levi M, van der Poll T.

J Immunol. 2007 Feb 1;178(3):1845-51.

16.

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.

Ann N Y Acad Sci. 2005 Nov;1059:160-7.

PMID:
16382051
17.

Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.

Berti R, Williams AJ, Velarde LC, Moffett JR, Elliott PJ, Adams J, Yao C, Dave JR, Tortella FC.

Neurotox Res. 2003;5(7):505-14.

PMID:
14715434
18.

Systematic discovery of multicomponent therapeutics.

Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7977-82. Epub 2003 Jun 10.

19.

Assays for proteasome inhibition.

Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES.

Methods Mol Med. 2003;85:163-72. Review. No abstract available.

PMID:
12710207
20.

Proteasome inhibition: a new anti-inflammatory strategy.

Elliott PJ, Zollner TM, Boehncke WH.

J Mol Med (Berl). 2003 Apr;81(4):235-45. Epub 2003 Mar 26. Review.

PMID:
12700891
21.

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ.

Blood. 2003 Jul 1;102(1):303-10. Epub 2003 Mar 13.

22.

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R.

Clin Cancer Res. 2003 Mar;9(3):1145-54.

24.

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM, Perez-Soler R.

Mol Cancer Ther. 2002 Aug;1(10):841-9.

25.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL.

J Clin Oncol. 2002 Nov 15;20(22):4420-7.

PMID:
12431963
26.

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS Jr, Nichols TC.

Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H919-26. Epub 2002 Nov 7.

27.

Early clinical experience with the novel proteasome inhibitor PS-519.

Shah IM, Lees KR, Pien CP, Elliott PJ.

Br J Clin Pharmacol. 2002 Sep;54(3):269-76.

28.

Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury.

Berti R, Williams AJ, Moffett JR, Hale SL, Velarde LC, Elliott PJ, Yao C, Dave JR, Tortella FC.

J Cereb Blood Flow Metab. 2002 Sep;22(9):1068-79.

PMID:
12218412
29.

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR.

Clin Cancer Res. 2002 Aug;8(8):2505-11.

30.

Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.

Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH.

J Clin Invest. 2002 Mar;109(5):671-9.

31.
32.
33.

The proteasome: a new target for novel drug therapies.

Elliott PJ, Ross JS.

Am J Clin Pathol. 2001 Nov;116(5):637-46. Review.

PMID:
11710679
34.

New agents in cancer clinical trials.

Adams J, Elliott PJ.

Oncogene. 2000 Dec 27;19(56):6687-92. Review. No abstract available.

35.

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP.

J Cell Biochem. 2001 Apr 2-27;82(1):110-22.

PMID:
11400168
36.

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr.

Cancer Res. 2001 May 1;61(9):3535-40.

37.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.

Cancer Res. 2001 Apr 1;61(7):3071-6.

38.

Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia.

Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC.

Stroke. 2000 Jul;31(7):1686-93.

PMID:
10884474
39.

Proteasome inhibition: a new strategy in cancer treatment.

Adams J, Palombella VJ, Elliott PJ.

Invest New Drugs. 2000 May;18(2):109-21. Review.

PMID:
10857991
40.

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ.

Clin Chem. 2000 May;46(5):673-83.

41.

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.

Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD.

J Autoimmun. 2000 May;14(3):205-11.

PMID:
10756082
42.

Proteasome inhibition: A novel mechanism to combat asthma.

Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J.

J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):294-300.

PMID:
10452747
43.

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ.

Am J Physiol. 1999 Aug;277(2):E332-41. doi: 10.1152/ajpendo.1999.277.2.E332.

PMID:
10444430
44.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ.

Cancer Res. 1999 Jun 1;59(11):2615-22.

45.

Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.

Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L, Adams J.

Methods Enzymol. 1999;300:345-63.

PMID:
9919536
46.

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15671-6.

47.

Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain.

Fike JR, Gobbel GT, Mesiwala AH, Shin HJ, Nakagawa M, Lamborn KR, Seilhan TM, Elliott PJ.

J Neurooncol. 1998 May;37(3):199-215.

PMID:
9524078
48.

Telomere length in myelodysplastic syndromes.

Boultwood J, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS.

Am J Hematol. 1997 Dec;56(4):266-71.

49.

Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7.

Bartus RT, Elliott PJ, Dean RL, Hayward NJ, Nagle TL, Huff MR, Snodgrass PA, Blunt DG.

Exp Neurol. 1996 Nov;142(1):14-28.

PMID:
8912895
50.

Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy.

Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT.

Exp Neurol. 1996 Oct;141(2):214-24.

PMID:
8812155

Supplemental Content

Loading ...
Support Center